Terms: = Sarcomas AND HIST1H3B, H3_1, P68431, H3FJ, H3/j, H3FF, H3/f, H3_f, H3FK, H3F1K, H3/k, H3FH, H3/h, H3FI, H3/i, H3FD, H3/d, H3FB, H3/b, H3FC, H3/c, H3FL, H3/l, H3FA, H3/A, ENSG00000124693, 8358 AND Treatment
4 results:
1. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract] [Full Text] [Related]
2. HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
La Noce M; Paino F; Mele L; Papaccio G; Regad T; Lombardi A; Papaccio F; Desiderio V; Tirino V
J Exp Clin Cancer Res; 2018 Dec; 37(1):296. PubMed ID: 30509303
[TBL] [Abstract] [Full Text] [Related]
3. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
[TBL] [Abstract] [Full Text] [Related]
4. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
[TBL] [Abstract] [Full Text] [Related]
